

Respiratory Disorder

## A Study of Pirfenidone in Patients With Unclassifiable Progressive Fibrosing Interstitial Lung Disease

**Trial Status**  
Completed

**Trial Runs In**  
14 Countries

**Trial Identifier**  
NCT03099187 2016-002744-17  
MA39189

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in participants with fibrosing interstitial lung disease (ILD) who cannot be classified with moderate or high confidence into any other category of fibrosing ILD by multidisciplinary team (MDT) review ("unclassifiable" ILD).

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT03099187 2016-002744-17 MA39189**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years & ≤ 85 Years

**Healthy Volunteers**  
No

---